Gilead Sciences Inc $102.27

up +1.48


21/8/2014 04:00 PM  |  NASDAQ : GILD  
Industries : Drugs / Biotechnology
Get Trend Analysis Icon Get GILD Trend Analysis - it has outperformed the S&P 500 by 54%

Partner Headlines

  1. New Magic Formula Stocks From Joel Greenblatt: CBI, DAL, GILD, MNST, ROST, ...

    GuruFocus
  2. Achillion Pharmaceuticals Up On Buyout Rumors

    IBD
  3. Jazz, Celgene Lead Top 4 Drugmaker Profit Margins

    IBD
  4. #PreMarket Primer: Monday, August 18: Jackson Hole Draws Market Attention

    Benzinga
  5. CNBC's Stock Pops & Drops From August 15

    Benzinga
  6. Gilead, Vipshop Lead Top 4 IBD 50 Stocks In EPS Gains

    IBD
  7. Gilead Wins Sovaldi Ruling

    IBD
  8. Biotech Leader Gilead Sciences Scores Sovaldi Win

    IBD
  9. Markets Close The Week On Negative Note As Ukraine Worries Mount

    Benzinga
  10. Stocks End Mixed, Off Session Lows; FleetCor Pads Gains

    IBD
  11. Gilead Wins Sovaldi Dispute With Roche, U.K. Nod

    IBD
  12. Julian Robertson Buys Tableau Software, Facebook, Netflix, Sells Ulta Salon, ...

    GuruFocus
  13. Apple, Facebook Among 5 Top Rated Big Cap Stocks

    IBD
  14. Intercept Pharma Soars On Liver-Disease Drug Data

    IBD
  15. After A Breakout, A Flat Base Can Yield New Entry

    IBD
  16. Tech, Health Care Lead Q2 Earnings Beats

    IBD
  17. #PreMarket Primer: Thursday, August 7: Russia Set To Release A List Of ...

    Benzinga
  18. Top 4 Stocks In The Biotechnology Industry With The Highest Revenue

    Benzinga
  19. Why Investors Should Closely Watch Celgene

    Benzinga
  20. TD Ameritrade Client Activity Jumped In July, Back To March Levels

    Benzinga
  21. TAL Education, Team Health Join The IBD 50 Resistance

    IBD
  22. Pharmacyclics Q2 Earnings Get Mixed Reception

    IBD
  23. Merck, J&J, Baxter Provide Healthy Dividend Stream

    IBD
  24. Aetna Earnings Beat But Rising Medical Costs A Worry

    IBD
  25. #PreMarket Primer: Monday, July 28: Tension Between U.S. And Israel On ...

    Benzinga
  26. Creating Cures And Dividends Where None Existed Before With Gilead Sciences

    GuruFocus
  27. Q2 Revenue Best Since 2012

    IBD
  28. Q2 Revenue Strongest Since 2012 As Recovery Quickens

    IBD
  29. AbbVie Beats Earnings Views, Sees Slower Humira Gain

    IBD
  30. Celgene, Alexion Beat Estimates, But Biotechs Fall

    IBD
  31. Celgene, Alexion Earnings Top Street, But Stocks Fall

    IBD
  32. Gilead Beats Q2 Views On Revenue Growth Lead By Sovaldi Drug

    Benzinga
  33. Biogen, Gilead Profits Soar

    IBD
  34. Biogen, Gilead Crush Earnings Estimates On Hot Drugs

    IBD
  35. Markets Mostly Higher As Earnings Season Continues To Impress

    Benzinga
  36. IPO Stock Watch: Biotechs Are Half Of July Calendar

    IBD
  37. Biogen Trounces Q2 Estimates As Tecfidera Outperforms

    IBD
  38. Statement from FDA Confirms Approval of Gilead's Zydelig

    Benzinga
  39. Earnings Scheduled For July 23, 2014

    Benzinga
  40. Alexion, 3 Other Top Biotechs Reporting Earnings

    IBD
  41. Biogen Shares Rebound As Street Has A Change Of Heart

    IBD
  42. Facebook, Gilead Headline IBD 50's Top 5 Earnings

    IBD
  43. Investors Focus On Earnings Rather Than Geopolitical Tensions

    Benzinga
  44. Biotech Enters Reporting Season With Large Caps Central To Sector Performance

    Benzinga
  45. Stocks Up In Late Trade; AerCap Nears Resistance

    IBD
  46. Stocks Add To Gains; Under Armour Rebounds

    IBD
  47. Yellen Swats Down Biotech, Social Media Stocks

    FoxBusiness
  48. J&J Earnings Beat Estimates, But Guidance Mixed

    IBD
  49. Economic News Today: Yellen Says Some Stock Valuations 'Stretched'

    IBD
  50. Biogen's Profit Rolls Amid Recent Drug Launches

    IBD
Trading Center